# A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

> **NCT02674321** · PHASE1 · COMPLETED · sponsor: **Auspex Pharmaceuticals, Inc.** · enrollment: 23 (actual)

## Conditions studied

- TOURETTE SYNDROME

## Interventions

- **DRUG:** SD-809

## Key facts

- **NCT ID:** NCT02674321
- **Lead sponsor:** Auspex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02674321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02674321, "A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02674321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*